A randomized, double-blind, placebo controlled, multi-center study of the pharmacodynamics/efficacy, tolerability, and pharmacokinetics of 3 fixed dosages of MEM 3454 (5 mg, 15 mg, and 50 mg) in patients with mild to moderate Alzheimer's disease

Trial Profile

A randomized, double-blind, placebo controlled, multi-center study of the pharmacodynamics/efficacy, tolerability, and pharmacokinetics of 3 fixed dosages of MEM 3454 (5 mg, 15 mg, and 50 mg) in patients with mild to moderate Alzheimer's disease

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2010

At a glance

  • Drugs RG 3487 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Memory Pharmaceuticals
  • Most Recent Events

    • 05 May 2008 The actual completion date for this trial is 1 Oct 2007.
    • 05 May 2008 Status changed from in progress to completed according to clinicaltrials.gov record.
    • 12 Jul 2007 Top-line results are expected in quarter 4, 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top